Lymphomas of the head and neck.

Abstract:

:Lymphomas of the head and neck arise in Waldeyer's ring, the salivary glands, nasal cavity, paranasal sinuses, thyroid gland, and orbit. Though anatomically in close proximity, lymphomas arising in these sites have distinct clinical characteristics. Factors that appear to influence the pattern of disease include concurrent conditions, such as Sjögren's syndrome, and geographic factors, particularly with regard to nasal lymphomas. The treatment and prognosis of patients with head and neck lymphoma depends on the histologic grade of disease and extent of involvement at time of presentation. Most lymphomas are of intermediate-grade histology and early stage at presentation. A thorough understanding of clinical disease patterns and treatment options will allow the optimum management of these patients.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Yuen A,Jacobs C

subject

Has Abstract

pub_date

1999-06-01 00:00:00

pages

338-45

issue

3

eissn

0093-7754

issn

1532-8708

journal_volume

26

pub_type

杂志文章,评审
  • The expanding role of cisplatin in the treatment of non-small-cell lung cancer.

    abstract::Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since the late 1970s. Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated p...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bunn PA Jr

    更新日期:1989-08-01 00:00:00

  • Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial.

    abstract::Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2. Because of toxicity, the weekly 5-FU dose in the combination treatment schedule was red...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Steinke B,Günther E,Hirschmann WD,Sondern W,Koniczek KH,Wander HE,Natt F,Wagner T,Hinrichs HF,Werdier D

    更新日期:1992-04-01 00:00:00

  • Epigenetics meets immune checkpoints.

    abstract::Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availab...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.02.003

    authors: Covre A,Coral S,Di Giacomo AM,Taverna P,Azab M,Maio M

    更新日期:2015-06-01 00:00:00

  • Carcinoembryonic antigen-based vaccines.

    abstract::Carcinoembryonic antigen (CEA) is a glycoprotein that is normally expressed in certain parts of the body and commonly overexpressed in most carcinomas of the colon, rectum, breast, lung, pancreas, and gastrointestinal tract. Increased expression of CEA promotes increased intercellular adhesions, which may lead to meta...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00233-1

    authors: Marshall J

    更新日期:2003-06-01 00:00:00

  • Metastatic and histologic presentations in unknown primary cancer.

    abstract::The patient with metastatic adeno- or undifferentiated carcinoma who presents with a cryptic primary is subjected to an extensive diagnostic search. These efforts apparently stem from the following assumptions: 1). The ultimately proven primary sites in such patients will occur with the same frequency as the most comm...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Nystrom JS,Weiner JM,Heffelfinger-Juttner J,Irwin LE,Bateman JR,Wolf RM

    更新日期:1977-03-01 00:00:00

  • Pathologic prognostic factors in esophageal carcinoma.

    abstract::Thus, many interesting and promising techniques are now available for the study of potential prognostic factors in esophageal carcinoma, and the results may supplement the information that is obtained by routine histopathologic analysis. It may become possible to define subgroups of patients with lower risk tumors, fo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Klimstra DS

    更新日期:1994-08-01 00:00:00

  • Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review.

    abstract:BACKGROUND:Patients with severe renal impairment or undergoing hemodialysis are usually excluded from clinical trials. Available data regarding safety and activity of systemic therapies (ST) in hemodialyzed patients are scarce. METHODS:Clinical data were searched through PubMed database until April 2020 according to P...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2020.05.001

    authors: Klajer E,Garnier L,Goujon M,Schlurmann-Constans F,Mery B,Nguyen Tan Hon T,Mouillet G,Calcagno F,Thiery-Vuillemin A

    更新日期:2020-01-01 00:00:00

  • Cardio-oncology in clinical studies and real life.

    abstract::Session V of the Colloquium was chaired by Professors Teresa López-Fernández of Spain and Grzegorz Opolski of Poland. The 3 speakers addressed cardio-oncology issues as they relate to both clinical studies and real life situations. Professor Susan Dent discussed cardio-oncology networks for patients, emphasizing the i...

    journal_title:Seminars in oncology

    pub_type:

    doi:10.1053/j.seminoncol.2019.01.004

    authors: Dent SF,Suter TM,López-Fernández T,Opolski G,Menna P,Minotti G

    更新日期:2019-12-01 00:00:00

  • Molecular biology of colorectal cancer: new targets.

    abstract::Colorectal cancer is an ideal model in which to study malignant progression from the molecular-genetic perspective because different stages of the same malignancy coexist within each patient. Approximately 75% of colorectal cancer cases are sporadic and the remaining are familial disease, yet genetic mutations that ha...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.10.003

    authors: Kitisin K,Mishra L

    更新日期:2006-12-01 00:00:00

  • Practical aspects of delivering hereditary cancer risk counseling.

    abstract::The primary element involved in the practical delivery of hereditary cancer risk counseling is the development of a cancer genetics service. This service should involve a multidisciplinary core of specialists, aim to identify at-risk individuals and their families, and provide comprehensive genetic counseling with the...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.07.003

    authors: DeMarco TA,Smith KL,Nusbaum RH,Peshkin BN,Schwartz MD,Isaacs C

    更新日期:2007-10-01 00:00:00

  • Metabolic emergencies in clinical oncology.

    abstract::As antineoplastic therapy improves, patients with cancer will have the potential for prolonged survival. Tumor products may produce metabolic complications, such as hypercalcemia, hyponatremia, and hypoglycemia, and these conditions must be promptly recognized so that treatment can be initiated before severe or life-t...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Silverman P,Distelhorst CW

    更新日期:1989-12-01 00:00:00

  • Radiation and carboplatin combined-modality therapy in non-small cell lung cancer.

    abstract::Previously untreated patients with stages I to IV, N0-3, M0 unresectable non-small cell lung cancer were randomized to arm I (conventional radiotherapy [RT], 60 Gy in 30 fractions over 6 weeks), arm II (accelerated RT, 60 Gy in 30 fractions over 3 weeks), arm III (conventional RT, as in arm I, plus carboplatin 70 mg/m...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Bishop JF,Ball D,Crennan E,Ryan G,Davis S,Toner G,O'Brien P,Olver I

    更新日期:1994-06-01 00:00:00

  • Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.

    abstract::In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU re...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Van Cutsem E,Blijham GH

    更新日期:1999-02-01 00:00:00

  • Management of side effects in patients with recurrent ovarian cancer.

    abstract::As with many other aspects of health care delivery in the United States, the entrenchment of managed care practices has significantly affected the management of patients with advanced ovarian cancer. Nurses continue to play a vital role in the delivery of health care in this venue, serving as the primary conduit betwe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Larrison EH

    更新日期:1999-02-01 00:00:00

  • Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer.

    abstract::Recurrent and second primary tumors arising within a previously radiated head and neck volume represent a difficult clinical scenario to manage. For patients who have resectable disease, surgery is the standard treatment. Chemotherapy is the standard for patients with unresectable or metastatic disease but offers no c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.03.010

    authors: Salama JK,Vokes EE

    更新日期:2008-06-01 00:00:00

  • The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.

    abstract::Letrozole has proven efficacious in a variety of therapeutic scenarios, including that of extended adjuvant therapy following 5 years of tamoxifen treatment in postmenopausal women with estrogen-receptor-positive early breast cancer. The Breast International Group 1-98 trial (BIG 1-98) is the first to study the effica...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1053/j.seminoncol.2006.03.026

    authors: Forbes JF

    更新日期:2006-04-01 00:00:00

  • Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging.

    abstract::Much recent debate has focused on the optimal classification of epithelial neuroendocrine tumors (NETs). Multiple different systems of terminology, grading, and staging have been proposed, and some systems combine elements of grade and stage into a single prognostic classification. Recently, national and international...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.11.001

    authors: Klimstra DS

    更新日期:2013-02-01 00:00:00

  • Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.

    abstract::The activity of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been documented in untreated and previously treated metastatic breast cancer, including both patients with anthracycline-resistant disease and those with extensive pretreatment. Such activity has prompted investigations of...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dombernowsky P,Gehl J,Boesgaard M,Jensen TP,Jensen BV

    更新日期:1996-02-01 00:00:00

  • Combination paclitaxel and platinum in the treatment of lung cancer: US experience.

    abstract::Despite marked improvements in the treatment options available for patients with lung cancers, more than 85% of patients ultimately relapse and die of their disease. Among the most auspicious of new agents available to treat lung cancers, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) also has been th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bunn PA Jr

    更新日期:1996-12-01 00:00:00

  • The use of chemotherapy as palliative treatment for patients with advanced ovarian cancer.

    abstract::Despite the high objective response rate of ovarian cancer to several reported platinum-based combination chemotherapy regimens, the majority of patients with advanced disease ultimately require consideration of a salvage regimen delivered for palliation of symptoms. A number of therapeutic strategies have been used i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Markman M

    更新日期:1995-04-01 00:00:00

  • New serum markers of hepatocellular carcinoma.

    abstract::Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, usually develops in a liver already suffering from chronic damages, often cirrhosis. There has been marked progress in the treatment of HCC. However, effective treatments are limited to patients with less advanced HCC. The detection of HCC at an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.05.009

    authors: Masuzaki R,Karp SJ,Omata M

    更新日期:2012-08-01 00:00:00

  • Management of early and locally advanced cervical cancer.

    abstract::Cervical cancer is the second most common malignancy in women and the third most common cause of cancer mortality worldwide. While primary and secondary preventions exist, the lack of widespread adoption leaves the treatment of cervical cancer an important oncologic problem. In this article, the management of early an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.12.007

    authors: Barbera L,Thomas G

    更新日期:2009-04-01 00:00:00

  • VP-16 and cisplatin in the treatment of non-small-cell lung cancer.

    abstract::The EORTC Lung Cancer Working Party investigated the effects of combination therapy with VP-16 (Ve-Pesid) and cisplatin in the treatment of non-small-cell lung cancer (NSCLC). Neither agent alone is recognized as being associated with a high rate of response in NSCLC, but the combination proved beneficial in our hands...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Klastersky J

    更新日期:1985-03-01 00:00:00

  • Measuring quality of life: an emerging science.

    abstract::Quality of life (QOL) variables are increasingly included as end points in cancer therapy trials, supplementing such traditional end points as survival time in evaluating the effects of cancer treatments. Consensus has been reached that a number of QOL components (symptom status and physical, emotional, role, and soci...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Moinpour CM

    更新日期:1994-10-01 00:00:00

  • Moving disease biology from the laboratory to the clinic.

    abstract::To address the urgent need for novel therapies for multiple myeloma (MM), long-term research efforts have characterized the mechanisms whereby MM cells home to the bone marrow and adhere to bone marrow stromal cells and extracellular matrix proteins. Research also characterizes the functional sequelae of this binding ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.34072

    authors: Anderson KC

    更新日期:2002-12-01 00:00:00

  • Treatment of newly diagnosed myeloma: Bortezomib-based triplet.

    abstract::We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall su...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2016.11.003

    authors: Rajan AM,Rajkumar SV

    更新日期:2016-12-01 00:00:00

  • Roadmap for new opportunities in melanoma research.

    abstract::Investigators representing all major melanoma research areas present an overview of the most important challenges for the field. Four major research areas are covered plus the training of new investigators. For each area we first describe the present status, its strengths and weaknesses, and then outline specific reco...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.09.004

    authors: Herlyn M,Halaban R,Ronai Z,Schuchter L,Berwick M,Pinkel D

    更新日期:2007-12-01 00:00:00

  • The new staging system for cutaneous melanoma in the era of lymphatic mapping.

    abstract::In 2002, the American Joint Committee on Cancer (AJCC) revised the staging system for cutaneous melanoma on the basis of a survival analysis of important melanoma prognostic factors. Features of the revised system include new strata for primary tumor thickness, incorporation of primary tumor ulceration as an important...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.018

    authors: Rousseau DL Jr,Gershenwald JE

    更新日期:2004-06-01 00:00:00

  • Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.

    abstract::To improve the resectability and long-term local control of locally advanced rectal cancer, we have initiated a radiation dose-escalation trial. It is hoped that the radioprotector amifostine will sufficiently reduce rectal morbidity (without also reducing tumor response) to permit increasing radiation doses. Only 6 p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/sonc.2002.37360

    authors: Myerson R,Zobeiri I,Birnbaum E,Dietz D,Fleshman J,Kodner I,Picus J,Ratkin G

    更新日期:2002-12-01 00:00:00

  • Intraperitoneal chemotherapy in the management of ovarian cancer.

    abstract::Initial phase I trials of intraperitoneal chemotherapy in ovarian cancer patients demonstrated that a pharmacologic advantage was achieved with the direct instillation of drugs into the peritoneal cavity. Recent trials have reported that approximately 30% of patients who have small-volume residual disease following in...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Ozols R

    更新日期:1985-09-01 00:00:00